Programme

Overview: This guideline session provides critical insights into the implementation of the "ESTRO/EANO recommendation on reirradiation of glioblastoma" guideline. The session offers a comprehensive analysis of the guideline's core components, centered on the nine key questions that formed the basis for 18 recommendations and nine expert statements. You will gain knowledge of patient selection criteria, imaging techniques for recurrence assessment, target volume delineation, treatment planning and combined treatment modalities. To enhance the guideline’s practical relevance, we will present two illustrative case reports. These real-world cases will demonstrate the application of the guideline's recommendations, highlighting both their potential uses and limitations in clinical practice.

Overview: Biochemical recurrence (BCR) after primary local treatment for prostate cancer remains a clinical challenge. Recent evidence suggests that high-risk non-metastatic BCR, defined by a rapid PSA doubling time, warrants systemic treatment intensification with androgen receptor pathway inhibitors, which significantly delay metastasis, disease progression, and potentially improve survival. Next-generation imaging, particularly PSMA-PET, enables earlier detection of oligometastatic disease, refining treatment strategies. This has led to growing interest in metastasis-directed therapy (MDT), such as SBRT, as a means to improve clinical outcome in this disease setting. Emerging data indicate that MDT, either alone or in combination with systemic treatment, can improve progression-free survival and delay systemic progression. However, key questions remain regarding optimal patient selection, treatment sequencing, and long-term outcomes. This session will provide a state-of-the-art overview of management of high-risk BCR after prostate cancer primary local treatment, addressing current evidence and unmet clinical needs to refine personalized treatment strategies.